Cargando…

(18)F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients

OBJECTIVE: To evaluate amyloid-β deposition with (18)F-florbetaben (FBB) PET imaging against (11)C-PIB PET in cognitive normal controls (NC), mild cognitive impairment (MCI), and Alzheimer’s disease (AD) patients. METHODS: We recruited 45 subjects (15 in each group of NC, MCI, and mild/moderate AD)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yan, Li, Can, Yang, Hui, Wu, Yue, Xu, Baixuan, Zhang, Jinming, Wang, Ruimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405850/ https://www.ncbi.nlm.nih.gov/pubmed/32848542 http://dx.doi.org/10.3389/fnins.2020.00745

Ejemplares similares

Patterns of Focal Amyloid Deposition Using (18)F-Florbetaben PET in Patients with Cognitive Impairment
por: Chung, Sung-eun, et al.
Publicado: (2022)

(18)F-florbetaben Aβ imaging in mild cognitive impairment
por: Ong, Kevin, et al.
Publicado: (2013)

Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study
por: Matías-Guiu, Jordi A., et al.
Publicado: (2015)

(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids
por: Rowe, Christopher C., et al.
Publicado: (2017)

Early detection of amyloid load using (18)F-florbetaben PET
por: Bullich, Santiago, et al.
Publicado: (2021)

Comparison Between (18)F-Florapronol and (18)F-Florbetaben Imaging in Patients With Cognitive Impairment
por: Baik, Kyoungwon, et al.
Publicado: (2023)

(18)F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition
por: Baratto, Lucia, et al.
Publicado: (2018)

Feasibility of in vivo (18)F-florbetaben PET/MR imaging of human carotid amyloid-β
por: Bucerius, Jan, et al.
Publicado: (2017)

Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Whole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults Using (18)F-Florbetaben
por: Um, Yoo Hyun, et al.
Publicado: (2017)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
por: Son, Hye Joo, et al.
Publicado: (2018)

Dual-phase (18)F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer’s disease
por: Yoon, Hai-Jeon, et al.
Publicado: (2021)

The Impact of Amyloid-Beta Positivity with 18F-Florbetaben PET on Neuropsychological Aspects in Parkinson’s Disease Dementia
por: Na, Seunghee, et al.
Publicado: (2020)

Author Correction: Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain
por: Richards, Danielle, et al.
Publicado: (2014)

Quantitative (18)F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients
por: Zhao, Qian, et al.
Publicado: (2019)

Cross-Sectional Comparison of Small Animal [(18)F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models
por: Brendel, Matthias, et al.
Publicado: (2015)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

The correlation of neuropsychological evaluation with (11)C-PiB and (18)F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease
por: Park, Su Yeon, et al.
Publicado: (2020)

(18)F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

Evaluation of Imaging Windows for Tau PET Imaging Using (18)F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer’s Disease Patients
por: Chotipanich, Chanisa, et al.
Publicado: (2020)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Clinical Relevance of [(18)F]Florbetaben and [(18)F]FDG PET/CT Imaging on the Management of Patients with Dementia
por: Librizzi, Damiano, et al.
Publicado: (2021)

Ethnic comparison of pharmacokinetics of (18)F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects
por: Senda, Michio, et al.
Publicado: (2014)

Beta-amyloid imaging with florbetaben
por: Sabri, Osama, et al.
Publicado: (2015)

Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
por: Chandra, Avinash, et al.
Publicado: (2019)

Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases
por: Daerr, Sonja, et al.
Publicado: (2016)

Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice
por: Overhoff, Felix, et al.
Publicado: (2016)

[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020)

(18)F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
por: Park, Sohee, et al.
Publicado: (2021)

Alzheimer’s Disease Prediction Using Attention Mechanism with Dual-Phase (18)F-Florbetaben Images
por: Kang, Hyeon, et al.
Publicado: (2022)

A multicentre longitudinal study of flortaucipir ((18)F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia
por: Pontecorvo, Michael J, et al.
Publicado: (2019)

Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction
por: Hatashita, Shizuo, et al.
Publicado: (2013)

Arterial spin labeling versus (18)F-FDG-PET to identify mild cognitive impairment
por: Dolui, Sudipto, et al.
Publicado: (2019)

Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination
por: Laudicella, Riccardo, et al.
Publicado: (2021)

Regional Amyloid Deposition in Amnestic Mild Cognitive Impairment and Alzheimer's Disease Evaluated by [(18)F]AV-45 Positron Emission Tomography in Chinese Population
por: Huang, Kuo-Lun, et al.
Publicado: (2013)

In vivo Imaging With (18)F-FDG- and (18)F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease
por: Franke, Timon N., et al.
Publicado: (2020)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e9ke7o347sra0t83im2dvs3j3a